Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing, China.
Cell Biochem Biophys. 2012 Jan;62(1):257-65. doi: 10.1007/s12013-011-9273-6.
To evaluate the effectiveness and safety of autologous cytokine-induced killer (CIK) cells in elderly patients with diffuse large B-cell lymphoma. Peripheral blood mononuclear cells (PBMC) were isolated from nine elderly patients with diffuse large B-cell lymphoma. PBMCs were augmented by priming with interferon gamma (IFN-γ) followed by IL-2 and monoclonal antibody (mAb) against CD3. Autologous CIK cells (range 5 × 10(9)-1 × 10(10)) were then infused back to individual patients; infusion was repeated every 4 weeks for 32 weeks (eight cycles). Patients were assessed for changes in lymphocyte subgroup, tumor-related biological parameters, imaging characteristics, the condition of remission, quality of life (QOL), and survival. Prior to CIK infusion, two patients were in complete remission and seven patients were in partial remission. After autologous CIK cell transfusions, the proportion of CD3+, CD3+CD8+, and CD3+CD56+ cells were significantly increased compared with baseline (P < 0.05); whereas serum levels of β2-microglobulin and LDH were significantly decreased (P < 0.05). The lymphoma symptoms were reduced and QOL was improved (P < 0.05) in all patients. All patients achieved complete remission at study endpoint. No adverse reactions were reported. Autologous CIK cell immunotherapy is safe and efficacious for the treatment of elderly patients with diffuse large B-cell lymphoma.
评估自体细胞因子诱导的杀伤（CIK）细胞在老年弥漫大 B 细胞淋巴瘤患者中的有效性和安全性。从 9 例老年弥漫大 B 细胞淋巴瘤患者中分离外周血单个核细胞（PBMC）。通过用干扰素γ（IFN-γ）预刺激，然后用 IL-2 和针对 CD3 的单克隆抗体（mAb）扩增 PBMC。然后将自体 CIK 细胞（范围 5×10（9）-1×10（10））回输给各个患者；每隔 4 周输注一次，共 32 周（8 个周期）。评估患者淋巴细胞亚群、肿瘤相关生物学参数、影像学特征、缓解情况、生活质量（QOL）和生存情况的变化。CIK 输注前，2 例患者完全缓解，7 例患者部分缓解。自体 CIK 细胞输注后，与基线相比，CD3+、CD3+CD8+和 CD3+CD56+细胞的比例显著增加（P<0.05）；而β2-微球蛋白和 LDH 血清水平显著降低（P<0.05）。所有患者的淋巴瘤症状减轻，生活质量改善（P<0.05）。所有患者在研究终点时均达到完全缓解。未报告不良反应。自体 CIK 细胞免疫疗法治疗老年弥漫大 B 细胞淋巴瘤安全有效。
